Summary of Purpose
To test the hypothesis that nimodipine would reduce the frequency of death and of worsening by 30% compared with placebo.Read More →
The following dates are available for this trial. Trial information last updated on 10 October 2000.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Miles Inc., Bayer AG, the Horace W. Goldsmith Foundation, and the Remin Fund
Randomized, double-blind, multicenter clinical trial of 1,064 patients.